Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Takara Bio Inc. ( (JP:4974) ) has shared an announcement.
Takara Bio Inc. announced that its parent company, Takara Holdings Inc., has completed a tender offer for its common shares conducted from February 16 to April 6, 2026. As a result of the successful offer, Takara Bio’s shares will be delisted and will no longer trade on the Tokyo Stock Exchange, effectively increasing Takara Holdings’ control and removing the company from public equity markets.
Takara Holdings launched the tender offer with a minimum acceptance condition of 6,927,000 shares and offered to purchase up to 47,065,467 common shares. With the tender now completed, the transaction marks a strategic shift for Takara Bio’s shareholder base, with public investors exiting and the company transitioning into a more tightly held subsidiary structure under its parent.
The most recent analyst rating on (JP:4974) stock is a Hold with a Yen1162.00 price target. To see the full list of analyst forecasts on Takara Bio Inc. stock, see the JP:4974 Stock Forecast page.
More about Takara Bio Inc.
Takara Bio Inc. is a biotechnology company listed on the Prime Market of the Tokyo Stock Exchange under securities code 4974. It operates under the umbrella of Takara Holdings Inc., focusing on life sciences-related businesses and products within the broader Takara Group’s portfolio.
Average Trading Volume: 651,859
Technical Sentiment Signal: Hold
Current Market Cap: Yen137.2B
See more insights into 4974 stock on TipRanks’ Stock Analysis page.